Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568618 · ClinicalTrials.gov registry record · Early Phase 1
Patient and Provider Confidence and Satisfaction With the Clinical Use of CYP Genetic Variability
A Early Phase 1 study, sponsored by Defense and Veterans Center for Integrative Pain Management.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
NCT02568618 is a Early Phase 1 study that was terminated before completion, run by Defense and Veterans Center for Integrative Pain Management. The registered enrollment target is 27 participants.
The verdict
NCT02568618, a Early Phase 1 study, was terminated before completion, sponsored by Defense and Veterans Center for Integrative Pain Management.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study utilizes the Medication DNA Insight™ tests for pain and mental health medications. We are testing the pain and mental health medications commonly used in pain treatment. Subjects will give a sample of saliva that will be tested for the metabolism of the different medications. Consented providers will be given the results of the test and can determine whether to change the subject's medication regimen. Providers and subjects will be ask to complete surveys both pre and post visits. The purpose is to examine provider and patient satisfaction, confidence and certainty of using the test results.
Interventions
- GENETIC Pain Medication DNA Insight (TM) test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568618
The ClinicalTrials.gov registry entry for NCT02568618 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Defense and Veterans Center for Integrative Pain Management, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pain Medication DNA Insight (TM) test is the first listed.
NCT02568618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02568618 about?
NCT02568618 is a clinical study titled "Patient and Provider Confidence and Satisfaction With the Clinical Use of CYP Genetic Variability". This study utilizes the Medication DNA Insight™ tests for pain and mental health medications. We are testing the pain and mental health medications commonly used in pain treatment. Subjects will give a sample of saliva that will be tested for the metabolism of the different medications. Consented pr...
What is the current status of trial NCT02568618?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2015-07. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02568618?
The interventions under investigation include: Pain Medication DNA Insight (TM) test (GENETIC).
Who is sponsoring clinical trial NCT02568618?
This trial is sponsored by Defense and Veterans Center for Integrative Pain Management, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.